# A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19

> **NCT04347031** · PHASE2,PHASE3 · COMPLETED · sponsor: **Burnasyan Federal Medical Biophysical Center** · enrollment: 320 (actual)

## Conditions studied

- Pneumonia, Viral
- Respiratory Failure

## Interventions

- **DRUG:** Mefloquine
- **DRUG:** Hydroxychloroquine
- **COMBINATION_PRODUCT:** Mefloquine + azithromycin + / - tocilizumab
- **COMBINATION_PRODUCT:** Hydroxychloroquine + azithromycin + / - tocilizumab

## Key facts

- **NCT ID:** NCT04347031
- **Lead sponsor:** Burnasyan Federal Medical Biophysical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-08
- **Primary completion:** 2020-11-01
- **Final completion:** 2020-11-20
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04347031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04347031, "A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04347031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*